Furiex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2)

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today that avarofloxacin (USAN adopted, INN approval pending), has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA). Avarofloxacin is a Phase III-ready broad-spectrum fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin-structure infections, community-acquired pneumonia and has proven to be effective in treating methicillin-resistant staphylococcus aureus (MRSA) infections.